About HTG Molecular Diagnostics (NASDAQ:HTGM)
HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq lymphoma panel; HTG EdgeSeq microRNA whole-transcriptome assay; and HTG EdgeSeq DLBCL cell of origin assay. It also provides sample processing and molecular profiling of retrospective cohorts through its VERI/O laboratory; and designs custom panels for biopharmaceutical customers and research services, resulting from research and development collaboration agreements with biopharmaceutical customers. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company has a research collaboration with Insituto Valenciano de Oncologia on breast cancer recurrence risk. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HTGM
CUSIPN/A
Phone877-289-2615
Debt
Debt-to-Equity RatioN/A
Current Ratio1.34%
Quick Ratio1.26%
Price-To-Earnings
Trailing P/E Ratio-1.92
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.76 million
Price / Sales6.61
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-28.67
Profitability
EPS (Most Recent Fiscal Year)($1.79)
Net Income$-18,960,000.00
Net Margins-128.46%
Return on EquityN/A
Return on Assets-109.14%
Miscellaneous
Employees98
Outstanding Shares28,360,000
HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions
What is HTG Molecular Diagnostics' stock symbol?
HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics (NASDAQ:HTGM) posted its quarterly earnings data on Thursday, March, 22nd. The medical research company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.15. The medical research company earned $7.90 million during the quarter, compared to analysts' expectations of $7.05 million. View HTG Molecular Diagnostics' Earnings History.
When is HTG Molecular Diagnostics' next earnings date?
What price target have analysts set for HTGM?
3 brokerages have issued 1 year target prices for HTG Molecular Diagnostics' shares. Their forecasts range from $6.00 to $7.00. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $6.6667 in the next year. View Analyst Ratings for HTG Molecular Diagnostics.
Who are some of HTG Molecular Diagnostics' key competitors?
Some companies that are related to HTG Molecular Diagnostics include Nuvectra (NVTR), Marinus Pharmaceuticals (MRNS), Miragen Therapeutics (MGEN), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Scpharmaceuticals (SCPH), Teligent (TLGT), Protagonist Therapeutics (PTGX), Zafgen (ZFGN), Evolus (EOLS), Spero Therapeutics (SPRO), Spring Bank Pharmaceuticals (SBPH), Avid Bioservices (CDMO), Kamada (KMDA), Proteostasis Therapeutics (PTI), Intec Pharma (NTEC), Immupharma (IMM) and Helius Medical Technologies (HSDT).
Who are HTG Molecular Diagnostics' key executives?
HTG Molecular Diagnostics' management team includes the folowing people:
- Mr. Timothy B. Johnson, Pres, CEO & Director (Age 57)
- Mr. John L. Lubniewski, VP & Chief Bus. Officer (Age 54)
- Dr. Patrick C. Roche Ph.D., Sr. VP of Research & Product Devel. (Age 65)
- Mr. Shaun D. McMeans, VP of Fin. & Admin, Treasurer & CFO (Age 56)
- Dr. Debra A. Gordon Ph.D., J.D., VP, Chief Legal Counsel & Sec. (Age 58)
When did HTG Molecular Diagnostics IPO?
(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Has HTG Molecular Diagnostics been receiving favorable news coverage?
Media headlines about HTGM stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a daily sentiment score of 0.07 on Accern's scale. They also assigned news stories about the medical research company an impact score of 46.49 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are HTG Molecular Diagnostics' major shareholders?
HTG Molecular Diagnostics' stock is owned by many different of retail and institutional investors. Top institutional investors include
STONEPINE CAPITAL MANAGEMENT, LLC
(5.60%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo, Plc Glaxosmithkline and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.
How do I buy shares of HTG Molecular Diagnostics?
Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HTG Molecular Diagnostics' stock price today?
One share of HTGM stock can currently be purchased for approximately $3.44.
How big of a company is HTG Molecular Diagnostics?
HTG Molecular Diagnostics has a market capitalization of $97.54 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.
How can I contact HTG Molecular Diagnostics?
HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.
MarketBeat Community Rating for HTG Molecular Diagnostics (HTGM)
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
HTG Molecular Diagnostics (NASDAQ:HTGM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for HTG Molecular Diagnostics in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 93.80%. The high price target for HTGM is $7.00 and the low price target for HTGM is $6.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.6667 | $6.6667 | $5.6667 | $6.1667 |
| Price Target Upside: | 93.80% upside | 38.31% upside | 40.61% upside | 224.56% upside |
HTG Molecular Diagnostics (NASDAQ:HTGM) Consensus Price Target History
HTG Molecular Diagnostics (NASDAQ:HTGM) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
HTG Molecular Diagnostics (NASDAQ:HTGM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
HTG Molecular Diagnostics (NASDAQ HTGM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 7.31%
HTG Molecular Diagnostics (NASDAQ HTGM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/1/2017 | Shaun D Mcmeans | VP | Sell | 945 | $2.11 | $1,993.95 | |  |
| 11/1/2017 | Shaun D Mcmeans | CFO | Sell | 945 | $2.26 | $2,135.70 | 43,248 | |
| 10/16/2017 | Shaun D Mcmeans | VP | Sell | 946 | $2.27 | $2,147.42 | 44,193 | |
| 8/25/2017 | Holdings A/S Novo | Major Shareholder | Sell | 1,149,813 | $1.81 | $2,081,161.53 | | |
| 8/24/2017 | Holdings A/S Novo | Major Shareholder | Sell | 382,437 | $1.91 | $730,454.67 | | |
| 8/23/2017 | Holdings A/S Novo | Major Shareholder | Sell | 47,162 | $2.02 | $95,267.24 | | |
| 8/22/2017 | Holdings A/S Novo | Major Shareholder | Sell | 80,586 | $2.07 | $166,813.02 | 1,225,085 | |
| 3/27/2017 | Plc Glaxosmithkline | Insider | Sell | 300,000 | $10.15 | $3,045,000.00 | | |
| 4/4/2016 | Debra A Gordon | VP | Sell | 1,672 | $2.89 | $4,832.08 | 17,705 | |
| 4/4/2016 | John L Lubniewski | Insider | Sell | 796 | $2.89 | $2,300.44 | 25,114 | |
| 4/4/2016 | Shaun D Mcmeans | CFO | Sell | 1,601 | $2.89 | $4,626.89 | 20,151 | |
| 4/4/2016 | Tim B Johnson | CEO | Sell | 4,914 | $2.89 | $14,201.46 | 51,309 | |
| 3/14/2016 | Debra A Gordon | VP | Sell | 5,535 | $2.38 | $13,173.30 | 23,518 | |
| 3/14/2016 | John L Lubniewski | Insider | Sell | 6,889 | $2.38 | $16,395.82 | 31,200 | |
| 3/14/2016 | Patrick C Roche | SVP | Sell | 5,929 | $2.38 | $14,111.02 | 23,783 | |
| 3/14/2016 | Shaun D Mcmeans | CFO | Sell | 5,651 | $2.38 | $13,449.38 | 25,991 | |
| 3/14/2016 | Tim B Johnson | CEO | Sell | 10,621 | $2.38 | $25,277.98 | 63,964 | |
| 3/9/2016 | Debra A Gordon | VP | Sell | 3,256 | $2.69 | $8,758.64 | 24,729 | |
| 3/9/2016 | John L Lubniewski | Insider | Sell | 4,067 | $2.69 | $10,940.23 | 32,712 | |
| 3/9/2016 | Patrick C Roche | SVP | Sell | 3,491 | $2.69 | $9,390.79 | 25,081 | |
| 3/9/2016 | Shaun D Mcmeans | CFO | Sell | 3,325 | $2.69 | $8,944.25 | 27,228 | |
| 3/9/2016 | Tim B Johnson | CEO | Sell | 6,299 | $2.69 | $16,944.31 | 66,306 | |
| 8/24/2015 | Debra A Gordon | VP | Buy | 1,000 | $5.16 | $5,160.00 | 1,356 | |
| 8/18/2015 | Patrick C. Roche | SVP | Buy | 6,500 | $5.76 | $37,440.00 | 6,500 | |
| 8/11/2015 | John L Lubniewski | Insider | Buy | 5,000 | $7.67 | $38,350.00 | | |
| 5/11/2015 | A/S Novo | Major Shareholder | Buy | 365,106 | $14.00 | $5,111,484.00 | | |
(Data available from 1/1/2013 forward)
HTG Molecular Diagnostics (NASDAQ HTGM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Comparing HTG Molecular Diagnostics (HTGM) and Its Peers
www.americanbankingnews.com - April 20 at 9:22 PM |
| Analyzing HTG Molecular Diagnostics (HTGM) and Its Competitors
www.americanbankingnews.com - April 20 at 3:13 AM |
| HTG Molecular Diagnostics (HTGM) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - April 18 at 8:36 AM |
| HTG Molecular Diagnostics (HTGM) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 17 at 10:55 PM |
| HTG Molecular Diagnostics (HTGM) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 17 at 4:47 PM |
 | HTG Molecular Diagnostics (HTGM) Announces Promotion of John Lubniewski to President & COO
www.streetinsider.com - April 16 at 5:24 PM |
 | HTG Promotes John Lubniewski to President and Chief Operating Officer
finance.yahoo.com - April 16 at 5:24 PM |
| Comparing HTG Molecular Diagnostics (HTGM) & The Competition
www.americanbankingnews.com - April 13 at 3:24 PM |
| HTG Molecular Diagnostics (HTGM) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 11 at 11:52 PM |
| HTG Molecular Diagnostics (HTGM) vs. Its Peers Financial Analysis
www.americanbankingnews.com - April 11 at 5:31 AM |
| Comparing HTG Molecular Diagnostics (HTGM) & Its Competitors
www.americanbankingnews.com - April 11 at 3:17 AM |
| HTG Molecular Diagnostics (HTGM) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:42 PM |
| Head-To-Head Survey: HTG Molecular Diagnostics (HTGM) & Its Peers
www.americanbankingnews.com - April 10 at 1:30 AM |
| ValuEngine Lowers HTG Molecular Diagnostics (HTGM) to Strong Sell
www.americanbankingnews.com - April 7 at 8:50 PM |
| HTG Molecular Diagnostics (HTGM) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 6 at 11:39 AM |
| Reviewing HTG Molecular Diagnostics (HTGM) & Mettler-Toledo International (MTD)
www.americanbankingnews.com - April 5 at 12:11 PM |
| Head to Head Contrast: HTG Molecular Diagnostics (HTGM) vs. Bruker (BRKR)
www.americanbankingnews.com - April 3 at 7:33 PM |
| HTG Announces New Patent for Its Technology Issued in Japan
finance.yahoo.com - April 3 at 8:24 AM |
| HTG Molecular Diagnostics' (HTGM) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 1 at 10:29 AM |
| HTG Molecular Diagnostics (HTGM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 7:58 PM |
| HTG Molecular Diagnostics (HTGM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 28 at 11:56 AM |
| HTG Molecular Diagnostics (HTGM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 27 at 10:56 PM |
| HTG Molecular Diagnostics (HTGM) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 27 at 1:16 PM |
| HTG Molecular Diagnostics Secures Debt Facility with MidCap Financial
finance.yahoo.com - March 27 at 8:27 AM |
| HC Wainwright Reaffirms Buy Rating for HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - March 25 at 10:56 PM |
| HTG Molecular Diagnostics (HTGM) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 23 at 11:52 PM |
| HTG Molecular Diagnostics (HTGM) Price Target Raised to $7.00 at Canaccord Genuity
www.americanbankingnews.com - March 23 at 3:16 PM |
| HTG Molecular Diagnostics (HTGM) PT Raised to $7 at Canaccord Genuity - StreetInsider.com
www.streetinsider.com - March 23 at 8:19 AM |
 | HTG Molecular Diagnostics' (HTGM) CEO TJ Johnson on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 23 at 8:19 AM |
 | 3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD) - Investorplace.com
investorplace.com - March 23 at 8:19 AM |
| HTG Molecular Diagnostics (HTGM) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS
www.americanbankingnews.com - March 23 at 8:14 AM |
| 3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD)
investorplace.com - March 23 at 7:33 AM |
| HTG Molecular Diagnostics (HTGM) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 23 at 12:30 AM |
 | Earnings Scheduled For March 22, 2018 - Benzinga
www.benzinga.com - March 22 at 5:36 PM |
 | HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results - GlobeNewswire (press release)
globenewswire.com - March 22 at 5:36 PM |
| HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 22 at 5:36 PM |
| Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections
finance.yahoo.com - March 20 at 5:17 PM |
| Recent Analysis Shows Iridium Communications, TPI Composites, First Internet, Destination Maternity, HTG Molecular Diagnostics, and 8x8 Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - March 19 at 8:23 AM |
| HTG Molecular Diagnostics (HTGM) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 16 at 8:12 PM |
| HTG Molecular Diagnostics to Announce Fourth Quarter and Year-End Financial Results and Host Conference Call on Thursday, March 22
finance.yahoo.com - March 7 at 6:34 PM |
| HTG Announces New Australian Patent for Its Technology
finance.yahoo.com - March 6 at 8:15 AM |
| HTG Molecular Diagnostics (HTGM) Announces New Australian Patent
www.streetinsider.com - February 27 at 5:55 PM |
| HTG Molecular Diagnostics (HTGM) Announces New Australian Patent - StreetInsider.com
www.streetinsider.com - February 27 at 8:19 AM |
 | 4 Stocks to Watch on News & Technical Momentum
www.nasdaq.com - February 14 at 4:04 PM |
| HTG Molecular Diagnostics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:40 AM |
| HC Wainwright Analysts Give HTG Molecular Diagnostics (HTGM) a $6.00 Price Target
www.americanbankingnews.com - January 28 at 5:10 PM |
| HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 23 at 5:26 PM |
| HTG Molecular Diagnostics (HTGM) Prices 12M Share Common Offering at $2.90/Sh
www.streetinsider.com - January 21 at 5:16 PM |
| HTG Molecular Diagnostics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - January 19 at 5:44 AM |
| HTG Molecular Diagnostics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 19 at 5:44 AM |
HTG Molecular Diagnostics (NASDAQ:HTGM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
HTG Molecular Diagnostics (NASDAQ:HTGM) Income Statement, Balance Sheet and Cash Flow Statement
HTG Molecular Diagnostics (NASDAQ HTGM) Stock Chart for Sunday, April, 22, 2018
Loading chart…
